Table 1 Blinatumomab for B cell precursor acute lymphoblastic leukemia
|  | Weight ≥ 45 kg (fixed dose) | Weight < 45 kg (BSA-based dose) |
|---|---|---|
CR1 or CR2 with *MRD-positive patients | ||
 Cycles 1–4 | ||
  Days 1–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
  Days 29–42 | 14-day treatment-free interval | 14-day treatment-free interval |
Relapsed or refractory patients | ||
 Induction cycle 1 | ||
  Days 1–7 | 9 μg/day | 5 μg/m2/day (not to exceed 9 μg/day) |
  Days 8–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
  Days 29–42 | 14-day treatment-free interval | 14-day treatment-free interval |
 Induction cycle 2 | ||
  Days 1–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
  Days 29–42 | 14-day treatment-free interval | 14-day treatment-free interval |
 Consolidation cycles 3–5 | ||
  Days 1–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
  Days 29–42 | 14-day treatment-free interval | 14-day treatment-free interval |
 Continued therapy cycles 6–9 | ||
  Days 1–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
  Days 29–84 | 56-day treatment-free interval | 56-day treatment-free interval |